SMARCB1 (INI1)-deficient malignant melanocytic neoplasm with histologically confirmed vertebral metastases in a young adult: a case report
Clinical Scorecard: Case Report of a Young Adult with Malignant Melanocytic Neoplasm Lacking SMARCB1 (INI1) and Confirmed Vertebral Metastases
At a Glance
Category Detail
Condition Malignant Melanocytic Neoplasm Key Mechanisms Biallelic inactivation of the SMARCB1 gene and loss of nuclear INI1 protein expression. Target Population Young adults with SMARCB1-deficient tumors. Care Setting Oncology and pathology departments.
Key Highlights
A 21-year-old woman presented with a choroidal lesion and vertebral metastases. Histopathological examination revealed a malignant epithelioid neoplasm with rhabdoid features. Complete loss of INI1 expression was noted in tumor cells. The patient received palliative radiotherapy and systemic chemotherapy. Progressive disease occurred despite treatment, leading to death three years post-diagnosis. Guideline-Based Recommendations
Diagnosis
Integrated histopathologic, immunophenotypic, and molecular assessment is essential. Management
Palliative radiotherapy and systemic chemotherapy may be considered. Monitoring & Follow-up
Regular follow-up for disease progression and response to treatment. Risks
High risk of metastasis and poor prognosis associated with SMARCB1-deficient tumors. Patient & Prescribing Data
Young adults with SMARCB1-deficient malignant neoplasms.
Etoposide and ifosfamide were used in systemic chemotherapy.
Clinical Best Practices
Consider differential diagnosis for intraocular tumors with melanocytic differentiation. Utilize comprehensive molecular analysis for accurate diagnosis. Related Resources & Content
